Market news

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences

Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $47.36, acco

Harmony Biosciences (NASDAQ:HRMY) highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler’s virtual CNS Symposium. Peter Anastasiou, the company’s chief o

Motley Fool Press Release.

Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.

Tipranks Press Release.

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Harmony Biosciences Holdings (HRMY) has an average rating of overweight and mean price target of $45

Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and updated analyst price targets.

Moby summary of Harmony Biosciences Holdings, Inc.'s Q2 2026 earnings call

Harmony Biosciences Holdings Inc (HRMY) reports 30% revenue growth and advances its Orexin-2 agonist pipeline with strong safety and efficacy signals.

Harmony Biosciences (NASDAQ:HRMY) reported second-quarter net revenue of $261.3 million, up 30% from the prior-year period and 21% sequentially, as sales of its narcolepsy treatment WAKIX rebounded from seasonal market-access pressures earlier in the year. The company reiterated its 2026 net revenu

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of +31.96% and +3.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles; Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Event driven interest around Harmony Biosciences Holdings stock Fresh attention is turning to Harmony Biosciences Holdings (HRMY) after research firm Zacks assigned the stock a Rank #1 rating with a Value grade of A, highlighting its valuation metrics against industry averages. See our latest analysis for Harmony Biosciences Holdings. At a recent share price of US$35.24, Harmony Biosciences Holdings has seen its share price return dip over the past month but rise about 11% over 90 days. The 1...

Harmony Biosciences Holdings (HRMY) has an average rating of overweight and mean price target of $45

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Harmony Biosciences leads a screen of undervalued price-to-book stocks, highlighting companies with low valuations and projected long-term earnings growth.

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Harmony Biosciences Holdings (NasdaqGM:HRMY) announced that Chief Financial Officer Glenn Reicin has resigned. The company named Stephen Mollichella as interim Principal Financial Officer, effective upon Reicin’s departure. The change affects the senior finance leadership responsible for reporting, capital allocation, and investor communication. Harmony Biosciences focuses on therapies for rare neurological conditions, a segment that often depends on clear funding plans, clinical execution,...

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMY

Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.

PLYMOUTH MEETING, Pa., July 16, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the first

Harmony Biosciences announced the appointment of Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer to ensure continuity in financial leadership while it searches for a permanent CFO.